Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study
An erratum to this article was published (Endocr Pract, Sep 2024 ↗)
Main finding · MACEResult — go to the resultHazard ratio 0.64 95% CI 0.46–0.88Authors' conclusion
In patients with type 2 diabetes initially diagnosed with DFC, SGLT2i are effective in significantly reducing the hospitalization for heart failure and MACE rates. SGLT2i lower the amputation rates, especially in patients who have not previously had a LEA, than the dipeptidyl peptidase-4 inhibitor therapy.
Study context
- Population
- Patients with T2D without previous major adverse cardiovascular event (MACE) and newly diagnosed diabetic foot complications, Taiwan National Health Insurance Research Database (2004–2017)
- Exposure
- SGLT2i vs GLP-1 RA vs DPP-4i
- Outcome
- First MACE occurrence
Main finding
MACE
Hazard ratio
0.64
95% CI 0.46–0.88
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Hospitalization for HFSGLT2ivs DPP-4i | 0.54 (0.35–0.83) | |
| Amputation in patients without LEA at first DFC diagnosisSGLT2ivs DPP-4i | 0.28 (0.10–0.75) | |
| 0.10.31310Hazard ratio (log scale) |
Amputation in patients without lower extremity amputation (LEA) at first DFC diagnosis
- Amputation rates did not increase with SGLT2i in those with a history of peripheral artery disease or LEA
Secondary outcomes (MACE components, all-cause mortality, LEA), GLP-1 RA vs DPP-4i
- No significant differences between DPP-4i and GLP-1 RA users in secondary outcomes
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →